MarketLens

Has Madrigal Pharmaceuticals (MDGL) Cracked the Code for MASH

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Has Spotify Finally Cracked the Code to Consistent Profitability

6 months ago

Has the White House Finally Cracked the Code on Crypto Regulation

5 months ago

Did The RealReal Finally Crack the Code on Luxury Resale Profitability

6 months ago

Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti

6 months ago

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off

Madrigal Pharmaceuticals' stock could take off if Rezdiffra expands into MASH cirrhosis, significantly enlarging its addressable market, while its developing pipeline may reduce dependence on the drug...

MDGL

Stock News•1 months ago

Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates

Madrigal (MDGL) reported a Q2 loss of $1.99 per share, beating the Zacks Consensus Estimate of a $2.55 loss, though wider than the $1.9 loss a year ago.

MDGL

Stock News•1 months ago

Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

Inventiva reported preliminary H1 2026 cash, cash equivalents and revenues. The clinical-stage biopharma focuses on an oral MASH therapy.

IVA

Stock News•1 months ago

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

MBX Biosciences initiated with a speculative buy, driven by Canvuparatide's de-risked Phase 2 profile and differentiated dosing convenience. Phase 3 must address PK variability and long-term calcium c...

MBX